336 related articles for article (PubMed ID: 32535016)
1. Two decades of vaccine innovations for global public good: Report of the Developing Countries' Vaccine Manufacturers Network 20th meeting, 21-23 october 2019, Rio de Janeiro, Brazil.
Pagliusi S; Dennehy M; Homma A
Vaccine; 2020 Aug; 38(36):5851-5860. PubMed ID: 32535016
[TBL] [Abstract][Full Text] [Related]
2. Vaccines, inspiring innovation in health.
Pagliusi S; Dennehy M; Kim H;
Vaccine; 2018 Nov; 36(48):7430-7437. PubMed ID: 29789241
[TBL] [Abstract][Full Text] [Related]
3. The art of partnerships for vaccines.
Pagliusi S; Che Y; Dong S
Vaccine; 2019 Sep; 37(40):5909-5919. PubMed ID: 31447125
[TBL] [Abstract][Full Text] [Related]
4. Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities.
Hayman B; Bowles A; Evans B; Eyermann E; Nepomnyashchiy L; Pagliusi S
Vaccine; 2021 Feb; 39(8):1190-1194. PubMed ID: 33487466
[TBL] [Abstract][Full Text] [Related]
5. Vaccines: Shaping global health.
Pagliusi S; Ting CC; Lobos F;
Vaccine; 2017 Mar; 35(12):1579-1585. PubMed ID: 28237501
[TBL] [Abstract][Full Text] [Related]
6. Casting off vaccine supply charity -- the pace quickens. CVI goal: quality vaccines for all children.
CVI Forum; 1995 Oct; (10):9-13. PubMed ID: 12290725
[TBL] [Abstract][Full Text] [Related]
7. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
8. Strengthening vaccination policies in Latin America: an evidence-based approach.
Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
[TBL] [Abstract][Full Text] [Related]
9. Vaccine innovation prioritisation strategy: Findings from three country-stakeholder consultations on vaccine product innovations.
Mvundura M; Frivold C; Janik Osborne A; Soni P; Robertson J; Kumar S; Anena J; Gueye A; Menozzi-Arnaud M; Giersing B; Kahn AL; Scarna T; Kristensen D
Vaccine; 2021 Dec; 39(49):7195-7207. PubMed ID: 34412922
[TBL] [Abstract][Full Text] [Related]
10. Intellectual property rights and challenges for development of affordable human papillomavirus, rotavirus and pneumococcal vaccines: Patent landscaping and perspectives of developing country vaccine manufacturers.
Chandrasekharan S; Amin T; Kim J; Furrer E; Matterson AC; Schwalbe N; Nguyen A
Vaccine; 2015 Nov; 33(46):6366-70. PubMed ID: 26368398
[TBL] [Abstract][Full Text] [Related]
11. Gavi's Transition Policy: Moving From Development Assistance To Domestic Financing Of Immunization Programs.
Kallenberg J; Mok W; Newman R; Nguyen A; Ryckman T; Saxenian H; Wilson P
Health Aff (Millwood); 2016 Feb; 35(2):250-8. PubMed ID: 26858377
[TBL] [Abstract][Full Text] [Related]
12. Sustainable vaccine manufacturing in low- and middle-Income countries.
Hayman B; Kumar Suri R; Downham M
Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966
[TBL] [Abstract][Full Text] [Related]
13. Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012.
Pagliusi S; Makhoana M; Datla M; Leite L; Hendriks J; Gholami A; Huang W; Gao Y; Jadhav S; Harshavardhan GV; Wu Y; Suhardono M; Homma A
Vaccine; 2013 Jun; 31(31):3111-5. PubMed ID: 23684836
[TBL] [Abstract][Full Text] [Related]
14. Quality vaccines for all people: Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05-07th October 2015, Bangkok, Thailand.
Pagliusi S; Ting CC; Khomvilai S;
Vaccine; 2016 Jun; 34(31):3562-7. PubMed ID: 26947496
[TBL] [Abstract][Full Text] [Related]
15. Vaccines, our shared responsibility.
Pagliusi S; Jain R; Suri RK;
Vaccine; 2015 May; 33(19):2197-2202. PubMed ID: 25749248
[TBL] [Abstract][Full Text] [Related]
16. Advancing the National Immunization Program in an era of achieving universal vaccine coverage in China and beyond.
Chen S; Rodewald LE; Du AH; Tang S
Infect Dis Poverty; 2024 Mar; 13(1):25. PubMed ID: 38475849
[TBL] [Abstract][Full Text] [Related]
17. Strategies for vaccine-product innovation: Creating an enabling environment for product development to uptake in low- and middle-income countries.
Giersing B; Shah N; Kristensen D; Amorij JP; Kahn AL; Gandrup-Marino K; Jarrahian C; Zehrung D; Menozzi-Arnaud M
Vaccine; 2021 Dec; 39(49):7208-7219. PubMed ID: 34627624
[TBL] [Abstract][Full Text] [Related]
18. Tenth Technical Advisory Group (TAG) meeting on vaccine-preventable diseases.
EPI Newsl; 1992 Apr; 14(2):2-6. PubMed ID: 12285738
[TBL] [Abstract][Full Text] [Related]
19. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
[TBL] [Abstract][Full Text] [Related]
20. Access to vaccines in Brazil and the global dynamics of the Health Economic-Industrial Complex.
Gadelha CAG; Braga PSDC; Montenegro KBM; Cesário BB
Cad Saude Publica; 2020; 36 Suppl 2():e00154519. PubMed ID: 32876097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
